STOCK TITAN

Labcorp (NYSE: LH) EVP reports RSU vesting and tax share withholding

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported multiple equity compensation events in early February 2026. On February 6–7, 2026, a total of 1,424 Restricted Stock Units converted into an equal number of common shares at a stated price of $0 per share, reflecting vesting of prior awards.

To cover tax withholding obligations, the company withheld 239 common shares at $277.2 on February 6 and 166 and 53 common shares at $274.01 on February 9, as indicated by transaction code “F” and the tax footnote. After these transactions, Schroeder directly held 5,926.1426 common shares and 3,164 Restricted Stock Units, each RSU representing the contingent right to receive one Labcorp common share.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schroeder Mark S

(Last) (First) (Middle)
531 SOUTH SPRING STREET

(Street)
BURLINGTON NC 27215

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Pres Diagnostics & COO
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2026 M 743 A (1) 5,703.1426 D
Common Stock 02/06/2026 F(2) 239 D $277.2 5,464.1426 D
Common Stock 02/07/2026 M 517 A (1) 5,981.1426 D
Common Stock 02/07/2026 M 164 A (1) 6,145.1426 D
Common Stock 02/09/2026 F(2) 166 D $274.01 5,979.1426 D
Common Stock 02/09/2026 F(2) 53 D $274.01 5,926.1426 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/06/2026 M 743 (3) (3) Common Stock 743 $0 3,845(4) D
Restricted Stock Unit (1) 02/07/2026 M 517 (5) (5) Common Stock 517 $0 3,328(4) D
Restricted Stock Unit (1) 02/07/2026 M 164 (5) (5) Common Stock 164 $0 3,164(4) D
Explanation of Responses:
1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
2. Stock withholding to satisfy tax withholding obligations.
3. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.
4. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
5. The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2024 and are now fully vested.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Kathryn W. Kyle, Attorney-in-Fact for Mark S. Schroeder 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Labcorp Holdings Inc

NYSE:LH

LH Rankings

LH Latest News

LH Latest SEC Filings

LH Stock Data

23.59B
82.58M
0.34%
100.04%
3.31%
Diagnostics & Research
Services-medical Laboratories
Link
United States
BURLINGTON